DICE Therapeutics, Inc. (DICE)

INDIANAPOLIS , Aug. 9, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE). The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

INDIANAPOLIS , July 25, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire one minute past 11:59 p.m.

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.

Eli Lilly and Co (NYSE:LLY)'s $2.4 billion acquisition of DICE Therapeutics “makes strategic sense,” bolstering the global pharmaceutical company's presence in immunology, analysts at UBS said in a note on Wednesday.  UBS, which has a ‘Buy' rating and a 12-month price target of $498 for Eli Lilly, noted that the acquisition provides two oral IL-17 inhibitors DC-806 and DC-853, as well as additional pipeline opportunities to the company's profile.

Eli Lilly and Dice Therapeutics agreed to a $2.4 billion buyout on Tuesday. Lilly might have landed important new immunology drugs via this deal.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

Lilly plans to buy Dice Therapeutics for $2.4 billion to expand its immunology pipeline. Investors appear to approve of the deal's price tag.

Looking to enhance its product portfolio for immune-related diseases, an area where it has lagged behind the competition, Eli Lilly & Co. ( LLY , Financial) announced on Tuesday it is acquiring Dice Therapeutics Inc. ( DICE , Financial) in a deal valued at $2.4 billion.

Eli Lilly agreed to buy DICE Therapeutics for $2.4 billion. The deal values DICE shares at an almost 40% premium from Friday's close.

Markets opened the shortened trading week on Tuesday, June 20, 2023 with losses as oil stocks sank along with the price of crude.

Lilly is paying a 40% premium for Dice's shares. Dice is a clinical-stage biotech with six programs in its pipeline.

Biotech stocks to watch in the stock market now.

Dice Therapeutics Inc (NASDAQ:DICE) was last seen up 37.6% to trade at a fresh all-time high of $46.56, after  Eli Lilly (LLY) revealed it will buy the immunology drug maker for roughly $2.4 billion , or $48 per share, in an all-cash deal that is a 40% premium to DICE's last close.